terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.
Company profile
Ticker
TERN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
TERN stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
14 Mar 24
8-K
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
7 Feb 24
S-8
Registration of securities for employees
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
14 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
10 Oct 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
8 Aug 23
Latest ownership filings
4
Change in insider ownership
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
3
Emil Kuriakose
19 Mar 24
SC 13G
Point72 Asset Management, L.P.
7 Mar 24
4
Amy L. Burroughs
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.89 mm | 37.89 mm | 37.89 mm | 37.89 mm | 37.89 mm | 37.89 mm |
Cash burn (monthly) | 14.34 mm | 2.09 mm | 11.06 mm | 7.94 mm | 6.90 mm | 4.94 mm |
Cash used (since last report) | 97.79 mm | 14.25 mm | 75.42 mm | 54.16 mm | 47.04 mm | 33.69 mm |
Cash remaining | -59.89 mm | 23.64 mm | -37.53 mm | -16.27 mm | -9.15 mm | 4.21 mm |
Runway (months of cash) | -4.2 | 11.3 | -3.4 | -2.0 | -1.3 | 0.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 98 |
Opened positions | 9 |
Closed positions | 20 |
Increased positions | 31 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 307.85 bn |
Total shares | 76.02 mm |
Total puts | 13.90 k |
Total calls | 102.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 7.62 mm | $38.32 bn |
Vivo Capital | 6.66 mm | $33.49 bn |
Suvretta Capital Management | 6.04 mm | $30.39 bn |
Deep Track Capital | 6.00 mm | $30.18 bn |
FMR | 5.12 mm | $25.74 bn |
Vivo Capital VIII | 4.34 mm | $0.00 |
Venrock Healthcare Capital Partners III | 3.71 mm | $0.00 |
BLK Blackrock | 3.16 mm | $15.92 bn |
VR Adviser | 3.09 mm | $15.55 bn |
Flynn James E | 2.85 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.2 | 4,149 | 25.72 k | 268,573 |
3 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.2 | 30,047 | 186.29 k | 1,945,015 |
3 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.2 | 103,870 | 643.99 k | 4,023,741 |
2 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.65 | 3,050 | 20.28 k | 272,722 |
2 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.65 | 22,084 | 146.86 k | 1,975,062 |
2 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.65 | 76,346 | 507.70 k | 4,127,611 |
1 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.99 | 5,451 | 38.10 k | 275,772 |
1 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.99 | 39,411 | 275.48 k | 1,997,146 |
1 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | Yes | 6.99 | 136,255 | 952.42 k | 4,203,957 |
1 Mar 24 | Amy L. Burroughs | Stock Option Common Stock | Grant | Acquire A | No | No | 7.31 | 1,250,000 | 9.14 mm | 1,250,000 |
News
UBS Maintains Buy on Terns Pharma, Lowers Price Target to $18
27 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
21 Mar 24
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $19
15 Mar 24
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
15 Mar 24
Terns Pharma Q4 EPS $(0.29), Inline
14 Mar 24
Press releases
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
10 Apr 24
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
12 Mar 24
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
7 Mar 24
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
7 Feb 24
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
2 Feb 24